Test environment running 7.6.6

Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Recent advances in drug delivery systems for glaucoma treatment

Abstract

Glaucoma is a chronic eye disease and the second most leading cause of irreversible impaired vision in the world, which is primarily linked with high intraocular pressure (IOP). The treatment of glaucoma is currently challenging because of the innate mechanics of ocular barriers that limit the penetration of ophthalmic drugs. To tackle this, various carriers (inorganic-, polymeric-, hydrogel-, or contact lens–based) with specialized physical and chemical properties have been intensively studied. These carrier-drug formulations have shown significant improvement in various aspects, such as ocular barriers penetration, bioavailability, sustained release of drug, tissue targeting, and lowering the IOP. The delivery systems can be administered through various routes (intravitreal or periocular injection or systemic route), enabling the drugs to reach the damaged sites and help to recover the damaged optical nerves, thus considered an effective treatment strategy for glaucoma. In this review, we thoroughly investigate the recent advances in ocular delivery formulations focusing on glaucoma, including nanocarrier types, delivery route, and the efficacy in vitro and in vivo, clinical availability, and future outlook.

Description

Citation

Source

Materials Today Nano

Book Title

Entity type

Access Statement

License Rights

Restricted until